TREATING VIRAL INFECTION WITH NMD INHIBITORS
Provided herein are compositions, systems, and methods treating latent viral infection with an NMD inhibitor (e.g. to reactive the latent virus to lytic virus), in combination with an anti-viral agent. In certain embodiments, the latent viral infection is caused by EBV or KSHV. In other embodiments, cancer (e.g., caused by the virus) is treated by further administering an anti-cancer agent, such as an immunomodulatory agent..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 15. Feb. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
GACK MICHAELA [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29 |
---|
Patentnummer: |
US2024050426 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000378852 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA000378852 | ||
003 | DE-627 | ||
005 | 20240329155011.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000378852 | ||
035 | |a (EPA)US2024050426 | ||
035 | |a (EPA)82931097 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a GACK MICHAELA |e verfasserin |4 aut | |
245 | 1 | 0 | |a TREATING VIRAL INFECTION WITH NMD INHIBITORS |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-15, Last update posted on www.tib.eu: 2024-03-20, Last updated: 2024-03-29 | ||
520 | |a Provided herein are compositions, systems, and methods treating latent viral infection with an NMD inhibitor (e.g. to reactive the latent virus to lytic virus), in combination with an anti-viral agent. In certain embodiments, the latent viral infection is caused by EBV or KSHV. In other embodiments, cancer (e.g., caused by the virus) is treated by further administering an anti-cancer agent, such as an immunomodulatory agent. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a VAN GENT MICHIEL |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 15. Feb. |
773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/82931097/publication/US2024050426A1?q=US2024050426 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 15 |c 02 |